SHH De Novo receives approval to initiate clinical trials in China with TLR8 agonist DN1508052
Source: Date:2019-10-14
Shanghai De Novo pharmatech Co., Ltd. has received Clinical Trial Application Approval on October 14, 2019 from the National Medical Products Administration (NMPA) to conduct clinical trials in China with DN1508052.
沪公网安备 31011502005675号